| Affimed is a holding company. Through its subsidiary, Co. is enagaged as a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Co.'s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that harnesses the body's own immune defenses to fight tumor cells. The more potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Co. focuses its research and development efforts on proprietary programs: AFM13, and AFM11. The AFMD YTD return is shown above.
The YTD Return on the AFMD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AFMD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AFMD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.